Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CAR(-T)s are on the road

CAR(-T)s are on the road editorial memo (2020) 13:3–4 https://doi.org/10.1007/s12254-020-00576-2 Jakob D. Rudzki Received: 9 January 2020 / Accepted: 10 January 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 CAR-T cell therapies (chimeric antigen receptor-T or dual targeting concepts like CD19 and CD22 to- cell therapies) are increasingly becoming part of gether), and its standing in the current treatment al- clinical practice since the approval of two com- gorithm [2]. pounds tisagenlecleucel (Kymriah —Novartis, Mor- Two additional articles describe future aspects and ris Plains, NJ, USA) and axicabtagene ciloleucel current results of interesting approaches of CAR-T cell (Yescarta —Gilead/kite, Santa Monica, CA, USA) in therapies in the setting of multiple myeloma and AML 2017 in the US market and a bit later in 2018 in Europe without any current approval at the moment. Gunsil- and other parts of the world, as well. Starting with ius et al. summarized some exciting results of diverse r/r pALL (relapsed/refractory B-cell precursor acute constructs targeting BCMA (B-cell maturation anti- lymphoblastic leukemia) up to the age of 25 years gen) and CD19 – to mention a few – without forgetting and young adults (Kymriah) and continuing with recently published or presented results of very similar r/r DLBCL http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

CAR(-T)s are on the road

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/car-t-s-are-on-the-road-3XuagkFzGH
Publisher
Springer Journals
Copyright
Copyright © Springer-Verlag GmbH Austria, part of Springer Nature 2020
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-020-00576-2
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:3–4 https://doi.org/10.1007/s12254-020-00576-2 Jakob D. Rudzki Received: 9 January 2020 / Accepted: 10 January 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 CAR-T cell therapies (chimeric antigen receptor-T or dual targeting concepts like CD19 and CD22 to- cell therapies) are increasingly becoming part of gether), and its standing in the current treatment al- clinical practice since the approval of two com- gorithm [2]. pounds tisagenlecleucel (Kymriah —Novartis, Mor- Two additional articles describe future aspects and ris Plains, NJ, USA) and axicabtagene ciloleucel current results of interesting approaches of CAR-T cell (Yescarta —Gilead/kite, Santa Monica, CA, USA) in therapies in the setting of multiple myeloma and AML 2017 in the US market and a bit later in 2018 in Europe without any current approval at the moment. Gunsil- and other parts of the world, as well. Starting with ius et al. summarized some exciting results of diverse r/r pALL (relapsed/refractory B-cell precursor acute constructs targeting BCMA (B-cell maturation anti- lymphoblastic leukemia) up to the age of 25 years gen) and CD19 – to mention a few – without forgetting and young adults (Kymriah) and continuing with recently published or presented results of very similar r/r DLBCL

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Mar 3, 2020

There are no references for this article.